The landscape of genetic medicines for in vivo T cell reprogramming
Directly reprogramming immune cells inside patients' bodies could make CAR-T therapy simpler and more accessible than current approaches require.
Comprehensive landscape of in vivo T cell reprogramming platforms (LNPs, AAV, lentiviral vectors) delivering CAR genetic cargo directly in patients; identifies delivery, safety, and manufacturing bottlenecks versus ex vivo CAR-T with LNP-based platforms closest to clinical readiness. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- narrative_review
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Adv Drug Deliv Rev
Why it surfaced
In vivo CAR-T represents the next-wave cell therapy paradigm with major access and cost advantages over ex vivo manufacturing; comprehensive landscape from drug delivery experts in Advanced Drug Delivery Reviews; maps investment and partnership opportunities for next-generation immunotherapy pipeline.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.